On March 16, Changchun High And New Technology Industries (Group) Inc(000661) ( Changchun High And New Technology Industries (Group) Inc(000661) , Changchun High And New Technology Industries (Group) Inc(000661) ) disclosed the annual report. In 2021, the operating revenue was 10.747 billion yuan, an increase of 25.30% year-on-year; The net profit attributable to shareholders of listed companies was 3.757 billion yuan, a year-on-year increase of 23.33%; The non net profit deducted from shareholders of listed companies was 3.742 billion yuan, a year-on-year increase of 26.76%.
Changchun High And New Technology Industries (Group) Inc(000661) was founded in 1993 and listed on Shenzhen Stock Exchange in 1996. It is one of the earliest listed companies in Northeast China. It has four main companies: kinsay pharmaceutical, Changchun Bcht Biotechnology Co(688276) , Huakang pharmaceutical and high-tech real estate.
According to the 2021 annual report, the subsidiary kinsay pharmaceutical achieved a revenue of 8.198 billion yuan and a net profit of 3.684 billion yuan attributable to the owner of the parent company. Based on this data, Kinsey pharmaceutical has contributed more than 76% of its revenue and more than 98% of its net profit to Changchun High And New Technology Industries (Group) Inc(000661) company.
The core product of kinsay pharmaceutical is growth hormone. The main products are recombinant human growth hormone for injection (powder injection), recombinant human growth hormone injection (water injection), polyethylene glycol recombinant human growth hormone injection (long-term water injection). Previously, growth hormone was included in the centralized collection of 11 provinces and regions in Guangdong for the first time. The results of the proposed selection released on March 1 showed that Jinsai pharmaceutical powder injection growth hormone 10iu, 2.5iu and 4iu were proposed to be selected, with a decrease of about 52%.
It is worth mentioning that Changchun High And New Technology Industries (Group) Inc(000661) mentioned in the annual report that during the reporting period, “Guangdong public hospital drug centralized purchase alliance” launched the regional policy of centralized purchase of drugs and medical consumables. Due to the long duration of publicity, registration and quotation of centralized purchase policy, the trend of macro policy was superimposed, Many Biopharmaceutical Enterprises, including the company, have experienced severe tests, and the stock market value of listed companies has also suffered heavy losses.
In terms of industry policy risks, Changchun High And New Technology Industries (Group) Inc(000661) also mentioned that in recent years, the state has further deepened the reform of the medical and health system and continued to strengthen the management of the pharmaceutical industry. In the process of normalization, the pharmaceutical policy has imperceptibly promoted the transformation of the industry to the stage of “from existing to excellent” operation, and policies such as consistency evaluation, centralized procurement, national negotiation and medical insurance fee control, It brings multiple pressures to the production and operation of pharmaceutical enterprises, and makes the company continue to face the risks brought by changes in industrial policies.
Changchun Bcht Biotechnology Co(688276) is another core enterprise of Changchun High And New Technology Industries (Group) Inc(000661) and currently there are three vaccine products approved for marketing, including live attenuated varicella vaccine, human rabies vaccine and freeze-dried nasal spray influenza live attenuated vaccine. In 2021, the revenue was 1.202 billion yuan and the net profit attributable to the owner of the parent company was 244 million yuan.
Changchun High And New Technology Industries (Group) Inc(000661) said that during the reporting period, covid-19 epidemic and covid-19 vaccination had a certain impact on the vaccination rate of other vaccine products. Especially in the second half of 2021, on the basis of continuous covid-19 vaccination for people over the age of 18, covid-19 virus vaccination for people aged 3-17 has been launched all over the country, which has greatly affected the promotion and vaccination of Changchun Bcht Biotechnology Co(688276) main products live attenuated varicella vaccine and freeze-dried nasal spray live attenuated influenza vaccine in the short term. The more prominent impact is the promotion and vaccination of influenza vaccine. The vaccination of influenza vaccine has a strong seasonality, and the applicable population of nasal spray influenza vaccine in Changchun Bcht Biotechnology Co(688276) is 3-17 years old, which highly coincides with the key population of covid-19 vaccination in the same period, resulting in a great impact on the vaccine promotion in the overall influenza season.
Huakang pharmaceutical is mainly engaged in the R & D, production and sales of traditional Chinese medicine, covering cardio cerebrovascular, traditional Chinese medicine anti-inflammatory, women and children and other product lines. Its main products include xueshuxinmaining, Yinhua Biyanling tablets, Shuqing granules, Qingwei Zhitong pellets, etc. In 2021, the revenue was 642 million yuan and the net profit attributable to the owner of the parent company was 43 million yuan.
